ADVANCE study - 20 years later
AbstractA crucial point in the long-term, effective and safe management of type 2 diabetes is the data from clinical studies that allow us to make the right choice in favor of a particular drug. The results of the ADVANCE study demonstrated that taking gliclazide MR leads to a statistically significant reduction in the risk of micro-and macrovascular events in patients with type 2 diabetes, and the ADVANCE-ON study showed a real and available possibility of saving the results. Thus, after 20 years, the ADVANCE results remain relevant, and hypoglycemic therapy based on gliclazide MR should remain the cornerstone in the treatment of patients with type 2 diabetes.
Keywords:type 2 diabetes mellitus, ADVANCE, ADVANCE-ON, gliclazide MR
Funding. The study had no sponsor support.
Conflict of interests. The author declare no conflict of interests.
For citation: Ametov A.S. ADVANCE study - 20 years later. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2020; 9 (3): 11-2. DOI: https://doi.org/10.33029/2304-9529-2020-9-3-11-12 (in Russian)
References
■ Matthews D.R. ADVANCE. Diabetes Obes Metab. 2020; 22 (suppl 2): 3-4. DOI: https://doi.org/10.1111/dom.14014
■ ADVANCE Ma nagement Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease - preterax and diamicron MR controlled evaluation. Diabetologia. 2001; 44: 1118-20.
■ UKPDS GROUP. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. UKPDS-33. Lancet. 1998; 352: 837-53.
■ Gerstein H.C., Riddle M.C., Kendall D.M., et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007; 99: 34i-43i.